Wall Street Analysts Believe NeuroPace Could Rally 54.34 percent Heres is How to Trade

NPCE Stock  USD 11.44  0.09  0.78%   
About 56% of Neuropace's investor base is looking to short. The analysis of overall sentiment of trading Neuropace stock suggests that many investors are alarmed at this time. The current market sentiment, together with Neuropace's historical and current headlines, can help investors time the market. In addition, many technical investors use Neuropace stock news signals to limit their universe of possible portfolio assets.
  
The mean of analysts price targets for NeuroPace points to a 54.3 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Read at zacks.com
zacks News
  

Neuropace Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Neuropace can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Neuropace Fundamental Analysis

We analyze Neuropace's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neuropace using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neuropace based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Number Of Shares Shorted

Number Of Shares Shorted Comparative Analysis

Neuropace is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.

Neuropace Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neuropace stock to make a market-neutral strategy. Peer analysis of Neuropace could also be used in its relative valuation, which is a method of valuing Neuropace by comparing valuation metrics with similar companies.

Peers

Neuropace Related Equities

ELMDElectromed   3.32   
0%
100.0%
CVRXCVRx   3.22   
0%
96.0%
LUNGPulmonx Corp   1.79   
0%
53.0%
KIDSOrthopediatrics Corp   1.07   
0%
32.0%
CNMDCONMED   0.80   
0%
24.0%
FNAParagon 28   0.60   
0%
18.0%
ITGRInteger Holdings   0.00   
0%
0%
ANIKAnika Therapeutics   0.49   
14.0%
0%
NVRONevro Corp   0.53   
15.0%
0%
OFIXOrthofix Medical   0.57   
17.0%
0%
SRDXSurModics   0.58   
17.0%
0%
AORTArtivion   0.70   
21.0%
0%
IRMDIradimed   1.06   
31.0%
0%
GKOSGlaukos Corp   1.67   
50.0%
0%

Complementary Tools for Neuropace Stock analysis

When running Neuropace's price analysis, check to measure Neuropace's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuropace is operating at the current time. Most of Neuropace's value examination focuses on studying past and present price action to predict the probability of Neuropace's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuropace's price. Additionally, you may evaluate how the addition of Neuropace to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Equity Valuation
Check real value of public entities based on technical and fundamental data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios